LCI699
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cushings Disease
Conditions
Cushings Disease, Cushing Disease
Trial Timeline
Mar 23, 2011 → Oct 22, 2019
NCT ID
NCT01331239About LCI699
LCI699 is a phase 2 stage product being developed by Novartis for Cushings Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01331239. Target conditions include Cushings Disease, Cushing Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01331239 | Phase 2 | Completed |
| NCT00732771 | Phase 2 | Completed |
Competing Products
3 competing products in Cushings Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pasireotide with or without cabergoline | Novartis | Phase 2 | 52 |
| osilodrostat + LCI699 matching placebo | Novartis | Phase 3 | 77 |
| Pasireotide | Recordati | Pre-clinical | 20 |